header
About the TB Alliance
Board of Directors
Board of Directors The TB Alliance is a not-for-profit organization governed by a Board of Directors.
The Board assumes fiduciary responsibility for the TB Alliance and guides its business strategy, actions, and budget. A Chief Executive Officer leads the organization and is a member of the Board.

The Board consists of thirteen directors, elected for staggered three-year terms, and represents government agencies, pharmaceutical and biotechnology companies, private foundations, and non-governmental organizations.

An elected member of the Stakeholders Association serves as an ex-officio member of the Board of Directors. 		Board of Directors
  • Dr. Bruce Carter | Chair
    Executive Chairman of the Board, Immune Design
  • Dr. Jaap F. Broekmans
    Johns Hopkins Bloomberg School of Public Health
  • Dr. Jan Gheuens
    Senior Program Officer, Infectious Disease Development, Bill & Melinda Gates Foundation
  • Dr. Simba Gill
    Chief Executive Officer, moksha8 Pharmaceuticals
  • Ms. Julia Gregory
    President & Chief Executive Officer, Five Prime Therapeutics
  • Mr. Mark Kessel
    Managing Director, Symphony Capital LLC
  • Dr. Anthony MBewu
  • Dr. Carlos Morel
    Director, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ)
  • Mr. James T. Morris
    President, Pacers Sports and Entertainment
  • Dr. Melvin Spigelman
    President & Chief Executive Officer, Global Alliance for TB Drug Development
  • Dr. Maarten van Cleeff
    Director,The Tuberculosis Coalition for Technical Assistance (TBCTA), KNCV Tuberculosis Foundation


The Global Alliance for TB Drug Development is a not-for-profit, tax-exempt organization recognized under section 501(c)3 of the United States Revenue Code; contributions are tax-deductible in the United States. The Alliance is also registered in the Annex of the Belgian State Gazette for non-profit organizations, as of February 28, 2002.